Epirium Bio
Latest round
- Series A
Last raised
- Dec 2019
Total raised
- $85M
Investors
- 6
About Epirium Bio
Epirium Bio, Inc. is a biotechnology firm focused on developing innovative therapeutics for neuromuscular diseases.Founded in 2008, Epirium Bio, Inc. operates out of San Diego, US. The company specializes in therapeutics aimed at neuromuscular diseases, with its primary candidate, EPM-01, targeting Becker muscular dystrophy. Jon Taub serves as both CEO and founder.Epirium Bio specializes in the development of innovative therapeutics aimed at addressing significant unmet medical needs in neuromuscular diseases. The company's primary product candidate, EPM-01, is an orally bioavailable synthetic compound specifically targeting Becker muscular dystrophy, which has shown proof-of-concept in both preclinical and clinical studies for mitochondrial dysfunction. Epirium Bio’s proprietary platform revolves around its unique small molecules that enhance mitochondrial function and muscle health, with applications extending to conditions such as sarcopenia and spinal muscular atrophy. The company’s research and products are directed towards healthcare providers and institutions primarily located in the United States, with aspirations to expand into other developed markets that focus on muscle degenerative diseases.Epirium Bio's revenue model is centered on the development and commercialization of its therapeutic candidates, particularly EPM-01. The company engages in strategic partnerships and collaborations with healthcare entities, which may involve milestone payments and royalties upon successful product development and commercialization. Transactions typically occur through agreements with pharmaceutical companies and research institutions, focusing on the advanced clinical trials needed to bring its products to market. The company aims to expand its reach into new markets, specifically targeting developed regions with high needs for therapies related to muscle degenerative diseases. As these initiatives progress, Epirium Bio is focused on introducing new products designed to enhance patient care and address significant gaps in treatment options. The strategic partnerships formed will also strengthen their market entry and product development efforts.
Who invested in Epirium Bio
6 investors across 1 round
See all investors in Epirium Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 18, 2019
Amount
$85M
Investors
Questions about Epirium Bio
Who invested in Epirium Bio?
Epirium Bio has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Epirium Bio raised?
Epirium Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Epirium Bio last raise money?
Epirium Bio's most recent round on record is a Series A, in Dec 2019.
What does Epirium Bio do?
Epirium Bio is a biotechnology company.
Where is Epirium Bio headquartered?
Epirium Bio is headquartered in San Diego, US.
Which VCs invest in companies like Epirium Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Epirium Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Epirium Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.